Distinguishing poorly differentiated gastric lymphoma from adenocarcinoma is essential because the prognosis and modalities of treatment differ significantly.

Several endoscopic findings have been reported, including solitary ulcers, thickened gastric folds, mass lesions and nodules.

Diffuse large B-cell lymphomas of the stomach are primarily treated with chemotherapy with CHOP (cyclophosphamide+doxorubicine+vincristine+prednisone) with or without rituximab being a usual first choice.

Second line therapy for MALT lymphomas is usually chemotherapy with a single agent, and complete response rates of greater than 70% have been reported.

[7] Subtotal gastrectomy, with post-operative chemotherapy is undertaken in refractory cases, or in the setting of complications, including gastric outlet obstruction.